TY - JOUR
T1 - Successful islet autotransplantation in humans
T2 - Functional insulin secretory reserve as an estimate of surviving islet cell mass
AU - Teuscher, Adrian U.
AU - Kendau, David M.
AU - Smets, Yves F.C.
AU - Leone, John P.
AU - Sutherland, David E.R.
AU - Paul Robertson, R.
PY - 1998
Y1 - 1998
N2 - Islet autotransplantation for treatment of chronic painful pancreatitis in nondiabetic patients reliably establishes normoglycemia and phasic insulin secretion and can achieve prolonged insulin independence. Whether functional transplanted β-cell reserve is normal after intrahepatic islet transplantation is not known, nor is it known whether conventional measures of insulin secretion accurately reflect the functional β-cell mass. To determine insulin secretory reserve after islet transplant, we performed studies of glucose potentiation of arginine-induced insulin secretion (GPAIS) in eight recipients of intrahepatic islet autotransplants. All eight subjects (and matched, healthy controls) were studied cross-sectionally 49 ± 12 months posttransplant, and four subjects were studied pre- and posttransplant. Subjects had received a mean ± SE of 479,000 ± 79,000 islets, and all were insulin independent and normoglycemic at the time of study. Acute insulin responses to arginine, glucose, and GPAIS were significantly reduced after islet transplantation in both study groups. Importantly, the magnitudes of these three responses were highly correlated to the mass of islets transplanted (response to glucose: r = 0.84, P < 0.01; response to arginine: r = 0.69, P < 0.05; response to GPAIS = 0.81, P < 0.01). Data from hemipancreatectomized and normal control subjects generally agreed with the regression lines. These findings demonstrate that despite normoglycemia and insulin independence, recipients of intrahepatic islet transplantation have significantly reduced functional β-secretory reserve and that after islet transplantation, functional β-cell mass can be estimated by measurements of glucose and arginine-induced insulin responses. Thus, these measurements can be used to estimate the mass and functional capacity of islets surviving intrahepatic transplantation in humans.
AB - Islet autotransplantation for treatment of chronic painful pancreatitis in nondiabetic patients reliably establishes normoglycemia and phasic insulin secretion and can achieve prolonged insulin independence. Whether functional transplanted β-cell reserve is normal after intrahepatic islet transplantation is not known, nor is it known whether conventional measures of insulin secretion accurately reflect the functional β-cell mass. To determine insulin secretory reserve after islet transplant, we performed studies of glucose potentiation of arginine-induced insulin secretion (GPAIS) in eight recipients of intrahepatic islet autotransplants. All eight subjects (and matched, healthy controls) were studied cross-sectionally 49 ± 12 months posttransplant, and four subjects were studied pre- and posttransplant. Subjects had received a mean ± SE of 479,000 ± 79,000 islets, and all were insulin independent and normoglycemic at the time of study. Acute insulin responses to arginine, glucose, and GPAIS were significantly reduced after islet transplantation in both study groups. Importantly, the magnitudes of these three responses were highly correlated to the mass of islets transplanted (response to glucose: r = 0.84, P < 0.01; response to arginine: r = 0.69, P < 0.05; response to GPAIS = 0.81, P < 0.01). Data from hemipancreatectomized and normal control subjects generally agreed with the regression lines. These findings demonstrate that despite normoglycemia and insulin independence, recipients of intrahepatic islet transplantation have significantly reduced functional β-secretory reserve and that after islet transplantation, functional β-cell mass can be estimated by measurements of glucose and arginine-induced insulin responses. Thus, these measurements can be used to estimate the mass and functional capacity of islets surviving intrahepatic transplantation in humans.
UR - http://www.scopus.com/inward/record.url?scp=2642648673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2642648673&partnerID=8YFLogxK
U2 - 10.2337/diabetes.47.3.324
DO - 10.2337/diabetes.47.3.324
M3 - Article
C2 - 9519735
AN - SCOPUS:2642648673
VL - 47
SP - 324
EP - 330
JO - Diabetes
JF - Diabetes
SN - 0012-1797
IS - 3
ER -